Соль-чувствительность и артериальная гипертензия: фундаментальная патогенетическая взаимосвязь – мишень для фармакологических воздействий

1. Комитет экспертов РМОАГ/ВНОК. Диагностика и лечение артериальной гипертензии. Рекомендации РМОАГ/ВНОК. Системные гипертензии. 2010; 3: 5–26.
2. Kempner W. Treatment of heart and kidney disease and arteriosclerotic vascular disease with rice diet. Ann Intern Med 1949; 31 (5): 821–56.
3. Scheithauer KH. Arteriosclerosis and hypertension; the necessity of salt free diet. Dtsch Gesundheitspolit 1951; 6 (45): 1289–90.
4. Dahl LK, Leitl G, Heine M. Influence of dietary potassium and sodium/potassium molar ratios on the development of salt hypertension. J Exp Med 1972; 136 (2): 318–30.
5. Dahl LK. Salt and hypertension. Am J Clin Nutr 1972; 25 (2): 231–44.
6. Guyton AC, Coleman TG, Cowley AV et al. Arterial pressure regulation. Overridding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 1972; 52: 584–94.
7. Morgan T, Adam W, Gillies A et al. Hypertension treated by salt restriction. Lancet 1978; 1 (8058): 227–30.
8. Gillies AH, Carney SL, Smith AJ et al. Adjunctive effect of salt restriction on antihypertensive efficacy. Clin Exp Pharmacol Physiol 1984; 11 (4): 395–8.
9. Oliver WB, Cohen EL, Neel JV. Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a «no-salt» culture. Circulation 1975; 52: 146–51.
10. The INTERSALT Study Group. INTERSALT Study an international co-operative study on the relation of blood pressure to electrolyte excretion in populations. I. Design and methods. The INTERSALT Co-operative Research Group J Hypertens 1986; 4: 781–7.
11. Stamler J, Rose G, Elliott P et al. Findings of the International Cooperative INTERSALT Study Hypertension 1991; 17 (Suppl. 1): I9–15.
12. Dyer A, Elliott P, Chee D et al. Urinary biochemical markers of dietary intake in the INTERSALT study. Am J Clin Nutr 1997; 65 (Suppl. 4): 1246S–53.
13. Elliott P, Stamler J, Nichols R et al. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. Intersalt Cooperative Research Group. BMJ 1996; 312: 1249–53.
14. Mancilha-Carvalho JJ, Souza e Silva NA. The Yanomami Indians in the INTERSALT Study. Arq Bras Cardiol 2003; 80: 289–300.
15. Meneton P, Jeunemaitre X, de Wardener HE, MacGregor GA. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev 2005; 85: 679–715.
16. Pamies-Andreu E, Ramirez-Lorca R, Stiefel Garcia-Junco P. Renin-angiotensin-aldosterone system and G-protein beta-3 subunit gene polymorphisms in salt-sensitive essential hypertension.  J Hum Hypertens 2003; 17: 187–91.
17. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension 1996; 27: 481–90.
18. Hollenberg NK, Martinez G, McCullough M et al. Aging, acculturation, salt intake, and hypertension in the Kuna of Panama. Hypertens 1997; 29 (1 Pt.2): 171–6.
19. Cusi D, Barlassina C, Azzani T et al. Polymorphisms of -adducin and salt-sensitivity in patients with essential hypertension. Lancet 1997; 349: 1338–9.
20. Hunt SC, Cook NR, Oberman A et al. Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: trials of hypertension prevention phase II. Hypertens 1998; 32: 393–401.
21. Martin DN, Andreu EP, Ramirez Lorca R et al. G-protein beta-3 subunit gene C825 T polymorphism: influence on plasma sodium and potassium concentrations in essential hypertensive patients. Life Sci 2005; 77: 2879–86.
22. Cusi D, Barlassina C, Taglietti MV. Genetics of human arterial hypertension. J Nephrol 2003; 16: 609–15.
23. Mattson DL, Meister CJ, Marcelle ML. Dietary protein source determines the degree of hypertension and renal disease in the Dahl salt-sensitive rat. Hypertens 2005; 45: 736–71.
24. Ahn J, Varagic J, Slama M et al. Cardiac structural and functional responses to salt loading in SHR. Am  J Physiol 2004; 287: H767–72.
25. Yu Q, Larson DF, Slayback D et al. Characterization of high-salt and high-fat diets on cardiac and vascular function in mice. Cardiovasc Toxicol 2004; 4: 37–46.
26. Porrello ER, Huggins CE, Curl CI et al. Elevated dietary sodium intake exacerbates myocardial hypertrophy associated with cardiac-specific overproduction of angiotensin II. J Renin Angiotensin Aldosterone Syst 2004; 5: 169–75.
27. Ying WZ, Sanders PW. Dietary salt modulates renal production of transforming growth factor-beta in rats. Am. J Physiol 1998; 274: F635–41.
28. Frohlich ED, Varagic J. Sodium directly impairs target organ function in hypertension. Curr Opin Cardiol 2005; 20: 424–9.
29. Beil AH, Schmieder RE. Salt intake as a determinant of cardiac hypertrophy. Blood Pres. Suppl. 1995; 2: 30–4.
30. Weir MR. Impact of salt intake on blood pressure and proteinuria in diabetes: importance of the renin-angiotensin system. Miner Electrolyte Metab. 1998; 24: 438–45.
31. Law M. Salt, blood pressure and cardiovascular diseases. J Cardiovasc Risk 2000; 7: 5–8.
32. Weinberger MH, Fineberg NS, Fineberg SE et al. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertens 2001; 37 (2 Pt. 2): 429–32.
33. He J, Ogden LG, Vupputuri S et al. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA 1999; 282: 2027–34.
34. Tuomilehto J  Jousilahti P, Rastenyte D et al. Urinary sodium excretion and cardiovascular mortality in Finland: a prospective study. Lancet 2001; 357: 848–51.
35. Forte JG, Miguel JM, Miguel MJ et al. Salt and blood pressure: a community trial.  J Human Hypertens 1989; 3: 179–84.
36. Whelton PK, Appel LJ, Espeland MA. et al. Sodium restriction and weight loss in the treatment of hypertension in older persons. A randomized controlled trial of non-pharmacological interventions in the elderly (TONE). JAMA 1998; 279: 839–46.
37. Sacks FM, Svetkey LP, Vollmer WM et al. for the DASH-Sodium Collaboration Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344: 3–10.
38. Flack JM, Peters R, Shafi T et al. Prevention of hypertension and its complications: theoretical basis and guidelines for treatment. J Am Soc Nephrol 2003; 14: S92–8.
39. Manger WM, Simchon S, Stier CT et al. Protective effects of dietary potassium chloride on hemodynamics of Dahl salt-sensitive rats in response to chronic administration of sodium chloride. J Hypertens 2003; 21: 2305–13.
40. Beckmann SL, Os I, Kjedsen SE et al. Effects of dietary counseling on blood pressure and arterial plasma catecholamines in primary hypertension. Am J Hypertens 1995; 8: 704–11.
41. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357: 1601–8.
42. He FJ, MacGregor GA. How far should salt intake be reduced? Hypertension 2003; 42: 1093–9.
43. Bleich M, Greger R. Mechanism of action of diuretics. Kidney Int. 1997; 51 (Suppl. 59): S11–5.
44. Neutel JM, Saunders E, Bakris GL et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005; 7 (10): 578–86.
45. Chrysant SG, Neutel JM, Ferdinand KC. INCLUSIVE investigators. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial. J Natl Med Assoc 2009; 101 (4): 300–7.
46. Franklin SS, Neutel JM. Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors  J Clin Hypertens (Greenwich) 2010; 12 (7): 487–94.

В.В.Фомин*, А.А.Пулин

ГОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ
*fomin_vic@mail.ru

________________________________________________

V.V.Fomin*, A.A.Pulin
*fomin_vic@mail.ru